tbuckley/cabot-search huggingface dataset:
Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities
Authors: Xiang-Yu Wang, Wen-Wei Zhu, Zheng Wang, Jian-Bo Huang, Sheng-Hao Wang, Fu-Mao Bai, Tian-En Li, Ying Zhu, Jing Zhao, Xin Yang, Lu Lu, Ju-Bo Zhang, Hu-Liang Jia, Qiong-Zhu Dong, Jin-Hong Chen, Jesper B. Andersen, Dan Ye, Lun-Xiu Qin
Journal: Theranostics (2021)

Purpose: To establish a clinically applicable genomic clustering system, we investigated the interactive landscape of driver mutations in intrahepatic cholangiocarcinoma (ICC). Methods: The genomic data of 1481 ICCs from diverse populations was analyzed to investigate the pair-wise co-occurrences or mutual exclusivities among recurrent driver mutations. Clinicopathological features and outcomes were compared among different clusters. Gene expression and DNA methylation profiling datasets were analyzed to investigate the molecular distinctions among mutational clusters. ICC cell lines with different gene mutation backgrounds were used to evaluate the cluster specific biological behaviors and drug sensitivities. Results: Statistically significant mutation-pairs were identified across 21 combinations of genes. Seven most recurrent driver mutations (TP53, KRAS, SMAD4, IDH1/2, FGFR2-fus and BAP1) showed pair-wise co-occurrences or mutual exclusivities and could aggregate into three genetic clusters: Cluster1: represented by tripartite interaction of KRAS, TP53 and SMAD4 mutations, exhibited large bile duct histological phenotype with high CA19-9 level and dismal prognosis; Cluster2: co-association of IDH/BAP1 or FGFR2-fus/BAP1 mutation, was characterized by small bile duct phenotype, low CA19-9 level and optimal prognosis; Cluster3: mutation-free ICC cases with intermediate clinicopathological features. These clusters showed distinct molecular traits, biological behaviors and responses to therapeutic drugs. Finally, we identified S100P and KRT17 as "cluster-specific", "lineage-dictating" and "prognosis-related" biomarkers, which in combination with CA19-9 could well stratify Cluster3 ICCs into two biologically and clinically distinct subtypes. Conclusions: This clinically applicable clustering system can be instructive to ICC prognostic stratification, molecular classification, and therapeutic optimization.
Abstract 9801: Thiol-Disulfide Exchange Reaction Between Thioredoxin-1 (trx1) and Atg7 Promotes Transnitrosylation of Atg7
Authors: Shinichi Oka, Narayani Nagarajan, Gihoon NAH, Risa Mukai, Junichi Sadoshima
Journal: Circulation (2021)

Thioredoxin 1 (Trx1) reduces proteins with disulfide bonds. However, when the oxidoreductase activity of Trx1 is inactivated, Trx1 is S-nitrosylated at Cys73 and acts as a trans-nitrosylase. Glucose deprivation (GD) inactivates the oxidoreductase activity of Trx1 and stimulates autophagy in cardiomyocytes. We investigated how Trx1 mediates S-nitrosylation of Atg7 in response to GD, thereby stimulating autophagy. GD-induced autophagy, evaluated with tandem fluorescent LC3 (mRFP-GFP-LC3), was inhibited in the presence of Trx1C73S, a transnitrosylation defective mutant (Relative GFP/RFP under GD, control 0.75; Trx1C73S 0.95*; p&lt;0.05 vs. control), suggesting that Trx1 mediates GD-induced autophagy via Cys73. Mass spectrometric and biochemical analyses showed that Cys545-548 in Atg7, a thioredoxin motif (CXXC), undergoes thiol-disulfide exchange reactions with Trx1, whereas Atg7 Cys402 is S-nitrosylated by SNO-Trx1. Atg7 C402S impairs Atg7 functions, as evidenced by reduced LC3-II formation with and without bafilomycin (Baf) (relative LC3-II, Atg7: 2.5; Atg7C402S: 1.7*; Atg7 with Baf: 3.1; Atg7C402S with Baf: 1.6*; p&lt;0.05). Thus, S-nitrosylation at Cys402 promotes Atg7 function, thereby promoting autophagy. On the other hand, Atg7 C545/548S inhibited both binding of Atg7 to Trx1 and Atg7 S-nitrosylation, suggesting that Trx1 S-nitrosylates Atg7 at Cys402 during thiol-disulfide exchange reactions between Atg7 Cys545-548 and Trx1. Knockdown of Trx1 prevented whereas overexpression of Trx1 promoted GD-induced Atg7 oxidation. In vitro redox reactions revealed that Atg7 can reduce Trx1. Thus, Trx1 mediates GD-induced autophagy through the following mechanism: 1) GD induces Trx1 oxidation at Cys32-35; 2) oxidized Trx1 is S-nitrosylated at Cys73; 3) Atg7 is S-nitrosylated at Cys402 during thiol-disulfide exchange reactions between Trx1 Cys32-35 and Atg7 Cys545-548; and 4) S-nitrosylated Atg7 at Cys402 promotes autophagy.
Circulating Tumor DNA Integrated with Interim [18F]FDG PET Is Highly Effective in Predicting Outcome of Relapsed/Refractory Classical Hodgkin Lymphoma Treated with the Begev Regimen
Authors: Martina Di Trani, Francesca Ricci, Martina Sollini, Eleonora Calabretta, Vanessa Cristaldi, Stefanos Bonovas, Fabrizio Marino, Rita Mazza, Alessio Bruscaggin, Maria Cristina Pirosa, Arturo Chiti, Davide Rossi, Armando Santoro, Carmelo Carlo-Stella
Journal: Blood (2021)
Identification of Patients with Unprovoked Venous Thromboembolism and a Low Risk of Recurrence Estimated By the Vienna Prediction Model: A Prospective Cohort Management Study
Authors: Sabine Eichinger, Lisbeth Eischer, Hana Šinkovec, Paul Gressenberger, Thomas Gary, Marianne Brodmann, Georg Heinze, Paul A. Kyrle
Journal: Blood (2021)
Isolation of a T-Cell Clone Showing HLA-DRB1*0405-Restricted Cytotoxicity for Hematopoietic Cells in a Patient With Aplastic Anemia
Authors: Shinji Nakao, Akiyoshi Takami, Hideyuki Takamatsu, Weihua Zeng, Naomi Sugimori, Hiroto Yamazaki, Yuji Miura, Mikio Ueda, Shintaro Shiobara, Takeshi Yoshioka, Toshihiko Kaneshige, Masaki Yasukawa, Tamotsu Matsuda
Journal: Blood (1997)
Aryl Hydrocarbon Receptor (AHR) Gene Expression in AML Is Associated with FLT3-ITD+ AML and HLA-E Induced Immune Resistance Reversed By Ik-364
Authors: Jennifer N. Saultz, Evan F. Lind, Jeffrey W. Tyner, Kaelan Byrd, Shannon K. McWeeney, Yoko Kosaka, Karen McGovern, Lei Wang, Marta Sanchez-Martin
Journal: Blood (2021)
Association of Maternal History of Spontaneous Abortion and Stillbirth With Risk of Congenital Heart Disease in Offspring of Women With vs Without Type 2 Diabetes
Authors: Honglei Ji, Hong Liang, Yongfu Yu, Ziliang Wang, Wei Yuan, Xu Qian, Ellen Margrethe Mikkelsen, Anne Sofie Dam Laursen, GuangHong Fang, Guoying Huang, Maohua Miao, Jiong Li
Journal: JAMA Network Open (2021)

<h3>Importance</h3> The associations of maternal history of spontaneous abortion (SA) and stillbirth with congenital heart disease (CHD) remain elusive. <h3>Objective</h3> To evaluate the associations of maternal history of pregnancy loss with CHD in offspring and the role of maternal type 2 diabetes. <h3>Design, Setting, and Participants</h3> This population-based cohort study included singleton live offspring born between January 1, 1977, and December 31, 2016, identified through Danish national health registries. Statistical analysis was performed from October 1, 2019, through September 1, 2021. <h3>Exposures</h3> Maternal history of SA, with frequency varying from 1 or 2 to 3 or more episodes, and maternal history of single and multiple stillbirths. <h3>Main Outcomes and Measures</h3> Overall CHD identified by hospital diagnosis. Cox proportional hazard regression was used to estimate the hazard ratio (HR) of CHD. Diabetes was evaluated as a potential confounder and a potential effect modifier. <h3>Results</h3> Among 1 642 534 included offspring (mean [SD] age, 14.11 [8.39] years; 843 265 male [51.35%]), 246 669 (15.02%) were born to mothers with a history of SA and 9750 (0.59%) were born to mothers with a history of stillbirth. The HRs of CHD were 1.16 (95% CI, 1.13-1.20) for offspring with a maternal history of SA and 1.49 (95% CI, 1.32-1.68) for offspring with a maternal history of stillbirth. Significant dose-response associations were observed among offspring with a maternal history of 3 or more episodes of SA (HR, 1.60; 95% CI, 1.39-1.84) and those with maternal history of multiple stillbirths (HR, 2.75; 95% CI, 1.63-4.65). If only inpatient CHD cases were included, the risk of CHD was higher than that found in the main analysis, with HRs of 1.24 (95% CI, 1.19-1.30) for maternal history of SA and 1.78 (95% CI, 1.51-2.11) for maternal history of stillbirth. The observed associations were strengthened by maternal prepregnancy type 2 diabetes (HR for maternal history of SA, 1.65 [95% CI, 1.37-1.97]; HR for maternal history of stillbirth, 1.74 [95% CI, 1.06-2.85]). <h3>Conclusions and Relevance</h3> These findings suggest that offspring born to mothers with a previous SA or stillbirth, especially multiple episodes, or with prepregnancy type 2 diabetes were at a higher risk of being diagnosed with CHD. These findings may help identify women at increased risk in whom detailed fetal heart assessment may be cost-effective and highlight the importance of screening for type 2 diabetes in women of reproductive age.
Genomic and Transcriptional Characterization of Primary Mediastinal Large B Cell Lymphoma
Authors: Rebecca J Leeman-Neill, Devang Thakkar, Sarah L. Ondrejka, Eric D. Hsi, Amy Chadburn, Mateo Mejia Saldarriaga, Sarah C. Rutherford, Chad M. McCall, Tareq Aljurf, Matthew McKinney, Jean L. Koff, David L Jaye, Jonathon B. Cohen, Dina Sameh Soliman, Abner Louissaint, Choon Kiat Ong, Chee Leong Cheng, Lianne Lee, Amir Behdad, Peter H. Norgaard, Andrew G Evans, Rashmi S. Goswami, Ridas Juskevicius, Mary Ann Arildsen, Kikkeri N Naresh, Caroline J Roth, Sandeep S. Dave, Govind Bhagat
Journal: Blood (2021)
Dynamics of a disinhibitory prefrontal microcircuit in controlling social competition
Authors: Chaoyi Zhang, Hong Zhu, Zheyi Ni, Qiuhong Xin, Tingting Zhou, Runlong Wu, Guangping Gao, Zhihua Gao, Huan Ma, Haohong Li, Miao He, Jue Zhang, Heping Cheng, Hailan Hu
Journal: Neuron (2021)
TMOD-23. MODELING PEDIATRIC BRAIN CANCER WITH HUMAN ORGANOIDS
Authors: Luca Tiberi
Journal: Neuro-Oncology (2021)

Abstract Among children/infant brain tumors, Medulloblastoma (MB) is the most common and stands as a cause for a high percentage of morbidity and mortality among patients During the past few years, studies on human MB have uncovered the existence of four major MB groups: WNT, SHH, Group3 and Group4. Patients with Group3 MB currently have the worst outcome among the four groups, and nearly 50% are metastatic at the time of diagnosis. In the last 3 years in our laboratory, we have developed a novel pediatric Medulloblastoma organoid model. We generated human iPSC-derived cancer organoids upon c-MYC/OTX2 and C-MYC/Gfi1 overexpression, mimicking human MB genetic alterations. Furthermore, the use of DNA methylation signature in combination with MB-specific markers analysis indicates that our organoid-based cancer model recapitulates several features of human MB. Now, we are taking advantage of this technology to produce novel brain cancer organoids that we are using to address cancer biology questions.
Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study
Authors: Catherine Thieblemont, Michael Dickinson, Joaquin Martinez-Lopez, Arne Kolstad, Jason P Butler, Monalisa Ghosh, Leslie L. Popplewell, Julio C. Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie Jose Kersten, Charalambos Andreadis, Peter A. Riedell, P. Joy Ho, Jose Pérez-Simón, Andy Chen, Loretta Nastoupil, Bastian Von Tresckow, Andres JM Ferreri, Takanori Teshima, Piers EM Patten, Joseph P. McGuirk, Andreas Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Aiesha Zia, C Lobetti Bodoni, Aisha Masood, Stephen J. Schuster, Nathan H. Fowler, Martin H. Dreyling
Journal: Blood (2021)
Genomic Landscape and Clinical Features of Myeloproliferative Neoplasm (MPN) Patients with Auto-Immune and Inflammatory Diseases (AID)
Authors: Dikelele Elessa, Lin-Pierre Zhao, Rafael Daltro De Oliveira, Nabih Maslah, Juliette Soret-Dulphy, Emmanuelle Verger, Clemence Marcault, Nathalie Parquet, Pierre Fenaux, Lionel Ades, Emmanuel Raffoux, Stephane Giraudier, Olivier Fain, Bruno Cassinat, Jean-Jacques Kiladjian, Arsene Mekinian, Lina Benajiba
Journal: Blood (2021)
30-Year Cardiovascular Disease in Type 1 Diabetes: Risk and Risk Factors Differ by Long-term Patterns of Glycemic Control
Authors: Rachel G. Miller, Trevor J. Orchard, Tina Costacou
Journal: Diabetes Care (2021)

We hypothesized that there is heterogeneity in long-term patterns of glycemic control with respect to cardiovascular disease (CVD) development in type 1 diabetes and that risk factors for CVD differ by glycemic control pattern. Thus, we estimated associations between data-derived latent HbA1c trajectories and 30-year CVD risk in the Pittsburgh Epidemiology of Diabetes Complications (EDC) study of childhood-onset (<17 years old) type 1 diabetes.
Gender Disparities in Myelodysplastic Syndromes: Phenotype, Genotype, and Outcomes
Authors: Sara Marie Tinsley-Vance, Najla Al Ali, Somedeb Ball, Luis E. E. Aguirre, Akriti G Jain, David Kaldas, Onyee Chan, Eric Padron, Kendra Sweet, Jeffrey E. Lancet, Andrew T. Kuykendall, David A. Sallman, Rami S. Komrokji
Journal: Blood (2021)
Systolic blood pressure and mortality in South Africa : Evidence from a nationally representative cohort study.
Authors: Alpha Oumar Diallo, Mohammed K. Ali, Pascal Geldsetzer, Emily W. Gower, Trasias Mukama, Ryan G. Wagner, Justine Davies, Maarten Bijlsma, Nikkil Sudharsanan
Journal: The Lancet Healthy Longevity (2021)
Abstract 9079: Omentin Reduces Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in Apolipoprotein E Knockout Mice
Authors: LIXIN FANG, Koji Ohashi, Tomonobu Takikawa, Yuta Ozaki, Kunihiro Takahara, Toyoaki Murohara, Noriyuki Ouchi
Journal: Circulation (2021)

Background: Abdominal aortic aneurysm (AAA) is a life-threatening disease worldwide. Obesity is associated with an increased risk of AAA. Omentin is an adipokine, which is downregulated by obesity. Here we investigated the effect of omentin on angiotensin (Ang) II-induced AAA formation in apolipoprotein-E knockout (apoE-KO) mice. Methods and Results: ApoE-KO mice were crossed with transgenic mice expressing the human omentin in fat tissue (OMT-Tg mice). ApoE-KO/OMT-Tg and apoE-KO mice were subjected to continuous Ang II infusion. ApoE-KO/OMT-Tg mice exhibited a reduced maximal diameter of AAA compared with apo-E KO mice evaluated by macroscopic and ultrasound analyses. ApoE-KO/OMT-Tg mice showed a reduction of elastic fiber degradation in aorta compared with apoE-KO mice. ApoE-KO/OMT-Tg mice also displayed reduced expression levels of matrix metalloproteinase (MMP) 9, MMP2, pro-inflammatory mediators and macrophage surface marker, F4/80, in aortic walls compared with apo-E-KO mice. Conversely, intravenous administration of adenoviral vectors expressing omentin (Ad-OMT) significantly reduced maximal diameter and elastic fiber degradation of abdominal aorta after Ang II infusion in apoE-KO mice compared with control Ad-β-gal treatment. Treatment of human monocyte-derived macrophages with omentin protein attenuated activity and expression of MMP9 and NF-κB phosphorylation after stimulation with lipopolysaccharide. Treatment of human aortic smooth muscle cells with omentin protein attenuated activity and expression of MMP2 after stimulation with tumor necrosis factor α. The suppressive effects of omentin on MMP9 and MMP2 expression in macrophages and vascular smooth muscle cells were reversed by inhibition of PI3-kinase/Akt signaling or blockade of integrin αVβ3. Finally, continuous administration of PI3-kinase inhibitor LY294002 reversed the suppressive effects of Ad-OMT on maximal diameter and elastic fiber degradation of abdominal aorta in apoE-KO mice after Ang II infusion. Conclusion: Our data indicate that omentin acts as an adipokine that can attenuate Ang II-induced development of AAA by reducing MMP9 and MMP2 expression through the integrin αVβ3/PI3-kinase/Akt signaling in the vascular wall.
Long-Term Follow-up and Single-Cell Multiomics Characteristics of Infusion Products in Patients with Chronic Lymphocytic Leukemia Treated with CD19 CAR-T Cells
Authors: Alexandre V. Hirayama, Ye Zheng, Mark R. Dowling, Alyssa Sheih, Tinh-Doan Phi, Delaney R. Kirchmeier, Abby W. Chucka, Jordan Gauthier, David G. Maloney, Raphael Gottardo, Cameron J. Turtle
Journal: Blood (2021)
IRFinder-S: a comprehensive suite to discover and explore intron retention
Authors: Claudio Lorenzi, Sylvain Barriere, Katharina Arnold, Reini F. Luco, Andrew J. Oldfield, William Ritchie
Journal: Genome biology (2021)

Accurate quantification and detection of intron retention levels require specialized software. Building on our previous software, we create a suite of tools called IRFinder-S, to analyze and explore intron retention events in multiple samples. Specifically, IRFinder-S allows a better identification of true intron retention events using a convolutional neural network, allows the sharing of intron retention results between labs, integrates a dynamic database to explore and contrast available samples, and provides a tested method to detect differential levels of intron retention.
Novel Oncogenic Non-Coding RNA：circRIC8B Regulates Lipid Metabolism Via Mir-199b-5p /LPL Axis in Chronic Lymphocytic Leukemia
Authors: Hui Jin, Zijuan Wu, Lei Fan, Luqiao Wang, Xueying Lu, Danling Gu, Lei Cao, Jianyong Li
Journal: Blood (2021)
CD229 CAR T Cell Therapy for the Treatment of Relapsed B Cell Lymphoma
Authors: Michael Olson, Tim Luetkens, Fiorella Iglesias, Sabarinath Radhakrishnan, Jennie Y. Law, Stephanie Avila, Erica Vander Mause, Nicola J Camp, Erin Morales, Aaron P. Rapoport, Saurabh Dahiya, Joshua Brody, Alana Welm, Djordje Atanackovic
Journal: Blood (2021)
The Contribution of CD148, CD180 and CD200 Combination in the Diagnosis of Chronic B-Cell Lymphoproliferative Disorders
Authors: Laurent Miguet, Caroline Mayeur-Rousse, Alice Eischen, Anne-Cecile Galoisy, Delphine C. M. Rolland, Carine Gervais, Eric Jeandidier, Raoul Herbrecht, Luc-Matthieu Fornecker, Thibaut Fabacher, Razvan Bizoi, Laurent Mauvieux
Journal: Blood (2021)
Dye‐Sensitized Rare Earth Nanoparticles with Up/Down Conversion Luminescence for On‐Demand Gas Therapy of Glioblastoma Guided by NIR‐II Fluorescence Imaging
Authors: Zheng Liu, Baofeng Yun, Yaobao Han, Zhilin Jiang, Hongqin Zhu, Feng Ren, Zhen Li
Journal: Advanced Healthcare Materials (2021)

Abstract As the primary malignant tumor in the brain, glioblastoma exhibits a high mortality due to the challenges for complete treatment by conventional therapeutic methods. It is of great importance to develop innovative therapeutic agents and methods for treatment of glioblastoma. In this work, the imaging and therapy of glioblastoma are reported by using dye sensitized core‐shell NaYF 4 :Yb/Tm@NaYF 4 :Nd nanoparticles with strong up/down‐conversion luminescence, of which the ultraviolet up‐conversion emissions at 348 and 365 nm are significantly enhanced by nearly 28 times and used to control the release of SO 2 from 5‐Amino‐1,3‐dihydrobenzo[c]thiophene 2,2‐dioxide prodrug for gas therapy, and the second near‐infrared (NIR‐II) down conversion emission at 1340 nm is increased five times and applied for imaging. It is revealed that the released SO 2 molecules not only cause oxidative stress damage of tumor cells, but also induce their pro‐death autophagy by down‐regulating the expression of p62 and up‐regulating the ratio of LC3‐II/LC3‐I, ultimately inhibiting tumor growth. The work demonstrates the great potential of rare earth nano‐platform with functions of NIR‐II imaging and photo‐controlled gas therapy in the diagnosis and treatment of orthotopic glioblastoma.
Abstract 13736: Trends and Disparities in Mortality Rates From Acute Myocardial Infarction in United States Cancer Patients
Authors: Jacqueline T Vuong, Boback Ziaeian, Eric H Yang
Journal: Circulation (2021)

Introduction: Cardiovascular disease and cancer are major causes of morbidity and mortality in the United States. Risk of acute myocardial infarction (AMI) is elevated in cancer patients, which may be due to shared risk factors as well as the cardiotoxicity of oncologic therapies. This study aims to estimate the mortality burden from AMI in the United States cancer population and identify demographics of affected populations. Methods: Data were obtained from the multiple causes of death data files from CDC WONDER from 1999-2019. All deaths with ICD 10 code I21 for “acute myocardial infarction” listed as the underlying cause of death and ICD-10 codes C00-C97 for “malignant neoplasms” listed as a contributing cause of death were included. Age-adjusted mortality rates (AAMR) were calculated based on the 2000 United States standard population. Results: There were 98,414 deaths from AMI with underlying cancer between 1999 to 2019, comprising 33.7% of all AMI deaths, with AAMR of 1.41 deaths/100,000 (95% CI 1.40-1.42). Mortality rates were higher in men (2.18/100,000; 95% CI 2.16-2.20) than women (0.90/100,000; 95% CI 0.89-0.91); relative risk 2.42. Among racial groups, African Americans had the highest mortality rate 1.66/100,000 (95% CI 1.62-1.69). In overall demographics, African American males have the highest mortality rate, 2.66 deaths/100,000 (95% CI 2.59-2.73), followed by White American males (2.19 deaths/100,000 (95% CI 2.17-2.20). African American women had higher mortality rates than women of any other racial group (1.09 deaths/100,000 95% CI 1.06-1.13) (Figure). Conclusions: Cancer patients make up a significant portion of all deaths from AMI. Africans Americans and males are disproportionately affected, and efforts should be made to elucidate the pathophysiologic and socioeconomic explanations for these disparities.
Duplex Sequencing for Ultra-Low Frequency Measurable Residual Disease Detection in Adult Acute Myeloid Leukemia
Authors: Jacob Higgins, Megan Othus, Laura W. Dillon, Thomas H. Smith, Elizabeth Schmidt, Jeffry Yaplee, Fang Yin Lo, Charles C. Valentine, Jesse J. Salk, Brent L. Wood, Christopher S. Hourigan, Jerald P. Radich
Journal: Blood (2021)
CLL-Derived Exosomes Turn Endothelial Cells into IL-6 Producing Cells
Authors: Orit Uziel, Lian Lipshtein, Zinab Sarsor, Einat Beery, Shaked Bogen, Meir Lahav, Vitali Kliminski, Roded Sharan, Asia Gervits, Lorenzo Signorini, Shai Shimony, Pia Raanani, Uri Rozovski
Journal: Blood (2021)
Survey Describes How Patients With Arthritis Get Moving
Authors: Rebecca Voelker
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal